CeriBell (NASDAQ:CBLL) Trading Down 5.6% – Should You Sell?

CeriBell (NASDAQ:CBLL) shares traded down 5.6% during trading on Friday . The stock traded as low as $15.79 and last traded at $16.14. 23,163 shares changed hands during mid-day trading, a decline of 91% from the average session volume of 270,086 shares. The stock had previously closed at $17.10.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on the company. Canaccord Genuity Group reaffirmed a “buy” rating and set a $33.00 price target on shares of CeriBell in a report on Wednesday, February 26th. LADENBURG THALM/SH SH initiated coverage on CeriBell in a research note on Friday, April 4th. They issued a “buy” rating and a $32.00 target price for the company. Seven research analysts have rated the stock with a buy rating, According to MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $32.50.

CeriBell Price Performance

The stock’s 50-day simple moving average is $18.06.

CeriBell (NASDAQ:CBLL) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.36) earnings per share for the quarter, topping the consensus estimate of ($0.43) by $0.07. As a group, equities analysts expect that CeriBell will post -2.46 EPS for the current year.

Insider Buying and Selling at CeriBell

In other CeriBell news, CEO Xingjuan Chao sold 5,700 shares of the firm’s stock in a transaction dated Thursday, April 17th. The stock was sold at an average price of $15.02, for a total transaction of $85,614.00. Following the transaction, the chief executive officer now owns 746,451 shares in the company, valued at approximately $11,211,694.02. This trade represents a 0.76 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Over the last ninety days, insiders have sold 24,700 shares of company stock valued at $372,434.

Institutional Trading of CeriBell

A number of hedge funds have recently modified their holdings of CBLL. CenterBook Partners LP acquired a new stake in CeriBell in the first quarter worth $3,531,000. Deutsche Bank AG raised its stake in CeriBell by 0.4% during the 1st quarter. Deutsche Bank AG now owns 231,629 shares of the company’s stock worth $4,450,000 after buying an additional 842 shares during the period. Federated Hermes Inc. lifted its holdings in CeriBell by 111.3% during the first quarter. Federated Hermes Inc. now owns 786,751 shares of the company’s stock worth $15,113,000 after acquiring an additional 414,500 shares in the last quarter. KLP Kapitalforvaltning AS acquired a new position in CeriBell in the first quarter valued at about $36,000. Finally, Massachusetts Financial Services Co. MA increased its holdings in shares of CeriBell by 0.4% in the first quarter. Massachusetts Financial Services Co. MA now owns 416,908 shares of the company’s stock worth $8,009,000 after acquiring an additional 1,547 shares in the last quarter.

About CeriBell

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.